Comparing the current results to its competitors, Lenz Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Lenz Therapeutics Inc 's competitors' average revenue growth of 5.64 %, achieved in the same quarter.
Lenz Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 35.9 %
Lenz Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates within the biotechnology, pharmaceutical, and ophthalmology sectors, which are characterized by rapid technological advancements and a strong focus on intellectual property. It competes with large and specialty pharmaceutical, biotechnology, and ophthalmology firms, as well as academic, governmental, public, and private research institutions. Competitors generally possess greater financial resources and expertise in research, development, manufacturing, clinical trials, and marketing. The company’s product candidates compete with existing and emerging therapies based on efficacy, safety, convenience, cost, promotional efforts, and intellectual property protection.
In the treatment of presbyopia, competitors include AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Eyenovia, Glaukos, Johnson & Johnson, Orasis, OSRX Pharmaceuticals (an affiliate of Ocular Science), Viatris (through licensing of Opus Genetics’ presbyopia products), and Tenpoint. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors, while smaller or early-stage companies may also present competition through collaborations. The company also faces competition in recruiting qualified personnel and acquiring complementary technologies and intellectual property.
Protalix Biotherapeutics Inc. operates under a business model focused on the development, production, and commercialization of recombinant therapeutic proteins using plant cell culture technology, aiming to address unmet medical needs and provide innovative treatment options to patients worldwide.
Pluri Inc's business model revolves around providing digital solutions and services to various clients. They leverage their expertise and technology to offer customized software development, IT consulting, and digital marketing services. With a focus on delivering tailored solutions, Pluri Inc aims to meet the specific needs and goals of their clients and support their growth in the digital landscape.
Sources:
Lenz Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lenz Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
